{"id":"NCT04929249","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Randomized Study to Evaluate the Effect of an \"Inclisiran First\" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)","officialTitle":"A Randomized, Multicenter, Open-label Trial Comparing the Effectiveness of an \"Inclisiran First\" Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (â‰¥70 mg/dL) Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-06-25","primaryCompletion":"2023-09-15","completion":"2023-09-15","firstPosted":"2021-06-18","resultsPosted":"2024-09-19","lastUpdate":"2025-05-16"},"enrollment":450,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atherosclerotic Cardiovascular Disease"],"interventions":[{"type":"DRUG","name":"Inclisiran","otherNames":["Inclisiran First"]}],"arms":[{"label":"Inclisiran First","type":"EXPERIMENTAL"},{"label":"Usual Care","type":"NO_INTERVENTION"}],"summary":"The purpose of this study was to assess the effectiveness of an \"inclisiran first\" implementation strategy (addition of inclisiran to maximally tolerated statin therapy immediately upon failure to achieve acceptable LDL-C with maximally tolerated statin therapy alone) compared to usual care in an atherosclerotic cardiovascular disease (ASCVD) population.","primaryOutcome":{"measure":"Percent Change From Baseline in LDL-C","timeFrame":"Baseline, Day 330","effectByArm":[{"arm":"Inclisiran First","deltaMin":-60,"sd":null},{"arm":"Usual Care","deltaMin":-7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":43,"countries":["United States"]},"refs":{"pmids":["38593947"],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=2304"]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":234},"commonTop":["COVID-19","Blood creatine phosphokinase increased","Injection site pain","Type 2 diabetes mellitus","Urinary tract infection"]}}